Sabrina Yahiya

Sabrina Yahiya has a diverse work experience in scientific research and development. Sabrina is currently working as a Scientist at Kymab Ltd, a Sanofi company, where they are involved in the development of human monoclonal antibody-based therapies and vaccines for malaria and influenza. Prior to this, they were a BBSRC Flexible Talent Fellow at Harvard T.H. Chan School of Public Health, where they tested the efficacy of a novel antimalarial compound series and discovered the ability to block malaria transmission through mosquito topical application. Sabrina also holds a Ph.D. from Imperial College London, where they conducted research as a PhD Candidate.

Sabrina Yahiya's education history begins in 2013 when they enrolled at the University of Warwick. Sabrina pursued a Bachelor of Science (BSc (Hons)) degree in Biochemistry and completed their studies in 2016.

In 2016, Sabrina Yahiya joined Imperial College London to further their education. Sabrina enrolled in a Master of Research (MRes) program with a specialization in Drug Discovery and Development. Sabrina completed the program in 2017.

Continuing their commitment to education, Sabrina Yahiya stayed at Imperial College London and embarked on a Doctor of Philosophy (PhD) program in Infectious Diseases Drug Discovery in 2017. Sabrina is expected to complete their PhD in 2021.

The aforementioned information provides a chronological overview of Sabrina Yahiya's education history, highlighting their progression from a bachelor's degree to a master's degree and then a doctoral degree, all in the field of drug discovery and related disciplines.